Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Podobne zapisy

• Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
  od: Kroesen, B. J., i wsp.
  Wydane: (1994)
• Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
  od: Janssen, R. A., i wsp.
  Wydane: (1992)
• Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency.
  od: Fauvel, J P, i wsp.
  Wydane: (1995)
• Prolonged continuous infusion of low-dose rIL-2.
  od: Janssen, R. A., i wsp.
  Wydane: (1994)
• Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
  od: Martens, A., i wsp.
  Wydane: (1993)